



Miltenyi Bioindustry

Streamline analytical tech transfer through **Analytical Target Profile (ATP)** diligence and standardization

By Kitman Yeung, Miltenyi Biotec



In cell and gene therapy (CGT), as in other biopharmaceutical disciplines, every assay shipped from the analytical development (AD) lab carries invisible “analytics debt”. A couple of clean replicates and a tidy R^2 may satisfy discovery timelines, but the first time that method lands in a GMP suite, the interest comes due in the form of repeat robustness runs, gating-template drift, and 30-day FDA queries that nobody budgeted.

Two decades in technology transfer, analytical development, and quality control testing have taught me that the single most effective way to erase that debt is to draft the ATP before the first antibody lot is ordered – and to lock hardware, software, and reagents into a common platform on day one. When AD, analytical science and technology (ASAT), and quality control (QC) co-author the ATP, tech transfer ceases to be a fire-drill and becomes a checklist, resulting in investigational new drug (IND) packages that clear the desk on first pass and patient lots that release without corrective and preventive actions (CAPAs). In the pages that follow, I’ll show you the playbook – and the data – that turn that promise into auditable reality.

Lost in translation: Assay edition

What looks “bulletproof” during R&D can crumble under GMP lights. In the AD lab, an assay earns the label well-established after a few tidy replicates and a clean standard curve. Move that same method into a clinical-grade environment and the bar jumps: [ICH Q2 \(R2\)](#) demands dozens of runs, stress tests on every critical parameter, and statistics that prove accuracy, precision, and range every time a patient batch is released. In short, “bench-ready” \neq “validation-ready”, and the difference can decide whether your IND moves forward or hits a clinical hold.

Without an ATP that details accuracy, precision, and range up front, early-stage assays often arrive in QC with missing controls, undefined sample-suitability limits, and protocols that need a GMP overhaul – costing precious months. Positive/negative controls and pre-defined acceptance criteria are basic expectations for GMP readiness outlined in [ICH Q2\(R2\)](#) and [USP <1220>](#)¹.

Another difference between a well-established assay in the development lab versus the QC lab lies in the thoroughness of the protocol. Development protocols often omit exact volumes, mixing order, tolerance limits, or hold-time instructions that GMP QC procedures must spell out for repeatability. To minimize such gaps, it is essential that the

academic lab or AD team create an in-depth ATP as early as possible. An ATP is a forward-looking statement of the assay’s intended use and the quantitative performance criteria it must meet; the ATP’s content then drives decisions about processes, reagents, and instrumentation. Before the AD team enters the lab, its members should agree on a list of questions and then design experiments that will answer them, consistent with the risk-based, design of experiments (DoE) -oriented “enhanced approach” promoted in [ICH Q14](#). Ideally, each experiment will answer multiple questions, maximizing efficiency.

Defining the ATP early stops a recurring tech-transfer failure mode: discovering during validation that you never collected accuracy or robustness data across the full reportable range. With an ATP guiding experimental design, every dataset generated is statistically powered to prove the assay meets its acceptance criteria – saving the re-work that wrecks IND timelines.

A key challenge in assay qualification is generating reproducible data relevant to all critical assay parameters, including reagent concentrations, incubation time, and instrument settings. A robust qualification explores worst-case conditions – temperature excursions, hold-time delays,

reagent lots – to prove the assay can still meet its accuracy and precision targets. Every challenge is planned, justified, and fully documented; surprises belong in study design, not in production.

How can sponsors improve AD/QC collaboration?

Sponsors can streamline analytical tech transfer by tapping their CDMO’s in-house experts – especially analytical scientists within the Manufacturing Science and Technology (MSAT) group, who bring pre-validated templates, GMP instrumentation, and first-hand regulatory experience. At Miltenyi Bioindustry, ASAT is the pivotal bridge between Assay Development and GMP Quality Control. We take every method through late-stage optimization, ICH Q2/USP <1220> qualification, and smart gain-enabled instrument alignment; compile the complete tech-transfer and validation package; and train QC analysts worldwide.

After transfer, ASAT remains the assay’s technical steward: we trend performance data, advise on change-control strategy, and draft comparability or bridging protocols – while QC executes those studies and authors the final reports. In short, if a test reaches patient material, ASAT has made it GMP-ready and stands ready to support its ongoing robustness.

Before a single pipette tip is picked up, a joint AD-ASAT-QC team drafts the ATP. The ATP defines what the assay must measure, its reportable range, precision limits, and the practical constraints – such as reagent supply chain, incubation holds, and the matrix in which real patient samples will arrive. Skipping these discussions can haunt you later: a flow cytometry assay gated on healthy peripheral blood mononuclear cells (PBMCs) often undercalls rare subsets in patient samples, forcing a costly bridging study just when you’re preparing your IND. Early, cross-functional ATP planning prevents that detour.

As assays mature past proof-of-concept, ASAT takes coownership to drive late-stage optimization and full ICH Q2/USP <1220> qualification. ASAT designs robustness DoE, locks critical parameters, aligns instruments with Smart Gain, and assembles the tech-transfer package. Along the way, we sanity-check reagent supply, verify commercial-versus-development hardware differences, and close any documentation gaps so QC receives a method that is GMP-ready.

During late-stage assay optimization, ASAT leads the analytical risk assessment – identifying which parameters (e.g., incubation time, reagent lot, instrument voltage) could jeopardize accuracy or precision – while MSAT owns the broader process failure mode and effects analysis (FMEA). Using that joint risk matrix, we design targeted robustness studies: enough evidence to prove the assay meets its ATP, but no superfluous experiments that bloat the IND. Clear, risk-based data packages pre-empt most FDA questions and keep timelines intact.

Because FDA may ask for clarifications or additional data during its 30-day IND safety review, sponsors need an evidence package that is both focused and gap-free. ASAT’s role is to build that package: we design robustness studies around the ATP, organize the data so every table maps to a specific acceptance criterion, and earmark reserve samples in case follow-up work is required. When a question does arrive – whether in an information request, a clinical-hold letter, or an inactive-status warning – the sponsor can answer promptly without scrambling for new assays.

To keep development, MSAT, and QC pulling in the same direction, ASAT acts as the analytical integrator. We translate R&D know-how into GMP language, lock the critical parameters, and make sure every standard operating procedure (SOP) can be executed exactly as written. QC’s mandate is to follow that SOP without improvisation; ASAT’s mandate is to see that the SOP leaves no room for guesswork – whether that means drafting missing details ourselves or partnering with AD to refine each critical step. In short, ASAT owns the method’s technical integrity from late development through commercial lifecycle.




Figure 1: Cumulative IND submission timeline under different planning scenarios.

Outsourced analytics are a powerful resource

Analytical tech transfer succeeds only when qualified scientists run the right tools. Many start-ups excel at discovery biology but lack staff fluent in ICH-level assay validation. The solution is two-fold: invest in targeted training for your existing team, and fill remaining gaps by partnering with a CDMO whose ASAT group can 'parachute in' proven people and platforms. Identifying and closing those skill gaps early prevents months-long stalls when validation is on the critical path.

Screening CVs with AI tools can catch buzzwords, but it won't tell you whether a candidate has ever authored an ICH-grade validation or defended an assay in front of FDA. If your organization lacks that interview expertise – and you already plan to outsource manufacturing – partnering with a CDMO whose ASAT team is fully credentialed may be faster and safer than trying to build the skill set inhouse.

Ultimately, standardization is our fastest route from benchtop idea to GMP release test. On the Miltenyi Bioindustry flow cytometry platform, we lock three variables on day one: gating, reagents, and instrument settings.

- **Express Modes** embed a rule-based gating template in the MACSQuantify™ Software, so every analyst – and every site – reads the same cell populations in the same way.
- **Smart gain** then auto-aligns detector voltages across instruments, turning a multi site tech transfer into a software toggle instead of a six-week bridging study.
- **StainExpress™** Dry Antibody Cocktails replace handmixed liquid panels with lyophilized, QA-released lots that eliminate titer drift and shipping constraints.

The result? AD hands QC a package that's already validated on the very hardware, software, and reagents QC will use – cutting repeat qualifications and shaving months off the IND timeline. And because Miltenyi Bioindustry's CDMO floor runs the same locked tool-chain, sponsors gain an execution team that speaks the assay's native 'language' on day one.

Still, hardware drift is the silent killer of tech-transfer timelines. When an AD lab ships only a gating template, QC still has to scan detector voltages, prove linearity, and run a 20-sample comparability – six weeks of nonvalue-

add work. Miltenyi Biotec's Smart Gain slashes that to a mouse-click: the software aligns every MACSQuant® Flow Cytometer to a master bead profile, so the original gating template is validation-ready at any site on day one.

For cell processing, we apply the same philosophy: the CliniMACS Prodigy® runs in our AD suites, our CDMO cleanrooms, and scores of academic hospitals. One closed, GMP-compliant platform means no re-engineering or requalification when you scale from pilot lot to commercial batch – saving another three months and a round of process comparability.

Standardize early, sleep soundly later

The fastest IND filings follow a simple rule: lock every analytical variable you can before validation starts. At Miltenyi Bioindustry, we do that in three moves:

- 1. Write the ATP with all stakeholders in the room.** AD, ASAT, and QC hammer out precision, range, and sample matrix up-front, so no one is surprised when patient samples replace healthy donors.
- 2. Freeze hardware, software and reagents.** Express Modes and Smart Gain turn your gating template into a site-agnostic file; StainExpress Lyophilized Cocktails kill lot drift; CliniMACS Prodigy runs the same closed protocol from pilot to commercial.
- 3. Keep the assay in expert hands.** Miltenyi Bioindustry's ASAT group designs the robustness DoE, executes ICH Q2(R2) qualification, trains QC analysts worldwide and trends the assay post-launch. One team, cradle to lifecycle.

The impact we see in real programs:

- **40% reduction of gating-setup time**
- **2 validation repeats saved**
- **approximately 6 months faster from AD freeze to first-patient-in**



¹ Bray MA, Carpenter A; Imaging Platform, Broad Institute of MIT and Harvard. "Advanced Assay Development Guidelines for Image-Based High Content Screening and Analysis." 2017 Jul 8. In: Markossian S, Grossman A, Baskir H, *et al.*, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK126174/>

This publication is for general informational purposes only. While all reasonable care has been taken in the preparation of this publication, Miltenyi Biotec assumes no responsibility for damages or other liabilities due to the accuracy, completeness, or currency of the information herein provided. Changes are periodically made to the information herein; these changes will be incorporated in new editions of the publication. Miltenyi Biotec may make improvements and/or changes in the product(s) and/or the process(es) described in this publication at any time without notice.



Miltenyi Biotec Inc. | Phone +1 866 811 4466 | Fax +1 530 745 2806 | bioindustry@miltenyi.com | www.miltenyibioindustry.com
Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibioindustry.com to find your nearest Miltenyi Bioindustry contact.

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibioindustry.com to find your nearest Miltenyi Bioindustry contact. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. CliniMACS Prodigy, MACSQuant, MACSQuantify, Stain Express and the Miltenyi Bioindustry logo are registered trademarks or trademarks of Miltenyi Biotec B.V. & Co. KG and/or its affiliates in various countries worldwide. Copyright © 2025 Miltenyi Biotec and/or its affiliates. All rights reserved.